La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Doximity Croissance future
Future contrôle des critères 1/6
Doximity devrait augmenter ses bénéfices et son chiffre d'affaires de 5.7% et de 7.8% par an respectivement. Le BPA devrait croître de de 9% par an. Le rendement des capitaux propres devrait être 19.9% dans 3 ans.
Informations clés
5.7%
Taux de croissance des bénéfices
9.0%
Taux de croissance du BPA
Healthcare Services croissance des bénéfices | 31.1% |
Taux de croissance des recettes | 7.8% |
Rendement futur des capitaux propres | 19.9% |
Couverture par les analystes | Good |
Dernière mise à jour | 19 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns
Aug 10Doximity Faces Slower Revenue Growth As R&D Costs May Rise
Jul 23Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?
Jul 23At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?
Jul 01Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking
Jun 09Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)
May 17Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal
May 04Doximity: Significant Upside Remains, But Not Until The Growth Story Returns
Apr 29With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For
Apr 16Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Mar 26Doximity: Rating Upgrade To Buy As Outlook Turns Positive
Feb 21We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit
Feb 15What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?
Feb 13Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan
Jan 16Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital
Jan 04Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price
Dec 14Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism
Nov 10Doximity: Adding Value Using AI But Faces Near-Term Risks
Nov 01Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 30Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively
Sep 25Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook
Aug 24Doximity Earnings: Too Many Problems, Sell
Aug 09A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Jul 29Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching
Jul 09Doximity: Continue To See Positive Upside From Current Stock Level
Jul 05The Returns At Doximity (NYSE:DOCS) Aren't Growing
Jun 21Doximity: Digital Health Play With Strong Fundamentals
Jun 21A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Apr 07Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return
Mar 20Doximity: Good Business But Extremely Overvalued
Feb 18Doximity Q3 Earnings: Disappointing Results
Feb 10Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Dec 25Doximity: On The Right Path To Further Consolidate Market Share
Dec 22Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital
Dec 04Doximity up 16% after fiscal 2023 Q2 beats, FY revenue range includes consensus
Nov 10Doximity, down 9%, falls below IPO price
Oct 12Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
3/31/2027 | 612 | 187 | 240 | 250 | 10 |
3/31/2026 | 563 | 161 | 230 | 234 | 17 |
3/31/2025 | 519 | 147 | 203 | 212 | 17 |
6/30/2024 | 494 | 161 | 162 | 168 | N/A |
3/31/2024 | 475 | 148 | 178 | 184 | N/A |
12/31/2023 | 468 | 138 | 162 | 167 | N/A |
9/30/2023 | 448 | 123 | 160 | 165 | N/A |
6/30/2023 | 437 | 119 | 186 | 192 | N/A |
3/31/2023 | 419 | 113 | 173 | 180 | N/A |
12/31/2022 | 402 | 119 | 173 | 180 | N/A |
9/30/2022 | 384 | 141 | 151 | 159 | N/A |
6/30/2022 | 362 | 148 | 131 | 138 | N/A |
3/31/2022 | 344 | 133 | 121 | 127 | N/A |
12/31/2021 | 317 | 107 | 113 | 117 | N/A |
9/30/2021 | 277 | 57 | 110 | 114 | N/A |
6/30/2021 | 243 | 30 | 103 | 107 | N/A |
3/31/2021 | 207 | 22 | 78 | 83 | N/A |
12/31/2020 | 177 | 14 | 48 | 53 | N/A |
3/31/2020 | 116 | 11 | 22 | 26 | N/A |
3/31/2019 | 86 | 1 | 14 | 15 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DOCS ( 5.7% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de DOCS ( 5.7% par an) devraient croître plus lentement que le marché US ( 15.1% par an).
Croissance élevée des bénéfices: Les bénéfices de DOCS devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DOCS ( 7.8% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DOCS ( 7.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de DOCS devrait être faible dans 3 ans ( 19.9 %).